|
||||||||
Company Profile | ||||||||
Chairman | CEO | Spokesperson | Tel | Address | Date of Listing (Regular) | |||
---|---|---|---|---|---|---|---|---|
LEE, CHUNG-LIANG | CHEN KUO SHIH | LEE, YING-FEN | 6626-1166 | 8F.2,NO.2,Ln.609,Sec.5,Chongxin Rd.,Sanchong Dist.,New Taipei City 24159,TaiwaR.O.C. | 2009/07/20 | |||
Industry | Main Business | |||||||
Biotechnology and Medical Care | In 1989, sold only TORAY hemodialysis products, imported equipments and consumables for sale and service. Beginning in 1994 and 1995, imported new dialyzers from TERUMO and IDEMSA respectively for the Taiwan dialysis market. In 1998, we took the chance to be the agent of Roche for selling Recormon Epoetin. In July of 2002, Hi-Clearance Inc. started to sell Hemodialysis related products from GAMBRO. |
Market Information ( 2024/04/19 ) | |||||||||||
Shr. Vol. | Highest | Lowest | Closed | Change | Transaction | TurnOver(%) | long margin balance (1,000shr.) |
Short margin balance (1,000shr.) |
|||
---|---|---|---|---|---|---|---|---|---|---|---|
42.552 | 139.50 | 139.00 | 139.00 | 0.00 | 150 | .00 | 4 | 0 | |||
Trading method | Fun purchase price or securities pneeded on T day |
Announcement of Irregularity (2024/04/19) |
TPEx measures adopted (2024/04/19) |
With warrants | Can be shorted or margined? | Detail | |||||
Normal | N | N | N | N | Y | Today | History |
Financial Reports | |||||
---|---|---|---|---|---|
Cash Flows | Items | ||||
Amount (NT$ thousand) |
|||||
Cash flows from operating activities | |||||
Cash flows from investing activities | |||||
Cash flows from financing activities | |||||
Balance Sheets |
Current assets | ||||
Non-current assets | |||||
Total assets | |||||
Current liabilities | |||||
Non-current liabilities | |||||
Total liabilities | |||||
Share capital | |||||
Capital surplus | |||||
Retained earnings | |||||
Other equity interest | |||||
Treasury shares | |||||
Total equity attributable to owners of parent | |||||
Non-controlling interests | |||||
Total equity | |||||
Book Value per share(NT$) | |||||
Comprehensive Income | Operating revenue | ||||
Operating costs | |||||
Gross profit from operations | |||||
Operating expenses | |||||
Net other income (expenses) | |||||
Net operating income | |||||
Non-operating income and expenses | |||||
Profit before tax | |||||
Tax expense | |||||
Profit from continuing operations | |||||
Profit from discontinued operations | |||||
Profit | |||||
Other comprehensive income | |||||
Comprehensive income | |||||
Basic earnings per share |
Auditor's report on latest financial statements: auditor's report: |
More detail:MOPS。 |
Foreign issuers’ information is disclosed in consolidated statements. |